Hazards of interferon therapy for HBV-seronegative chronic hepatitis.
Vento
S
S
Di Perri
G
G
Garofano
T
T
Cosco
L
L
Concia
E
E
Ferraro
T
T
Bassetti
D
D
D000293:Adolescent; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
D006510:Hepatitis B Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins